c5089847-0e2f-4bcd-bf3d-f3a21bb9b330.pdf Valneva Announces Filing of its Registration Document Lyon (France), May 12, 2016 - Valneva SE ("Valneva"), a leading pure play vaccine company, announces today that it has filed its 2015 Registration Document ("Document de Référence") with the French market authority, the "Autorité des Marchés financiers," under the filing number D.16-0473.

Valneva's 2015 Registration Document includes the Company's 2015 Annual Financial Report and Corporate Social Responsibility Report.

It is available on the Company's corporate website (www.valneva.com/en/investors- media/registration-document) and on the AMF website (www.amf-france.org). A hard copy of the document may be obtained from the Company, free of charge, upon request at the following address: 6 rue Alain Bombard, 44800 Saint-Herblain, France.

About Valneva SE

Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine.

The Group seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.

Valneva's portfolio includes two commercial vaccines for travelers: one for the prevention of Japanese Encephalitis (IXIARO®/JESPECT®) and the second (DUKORAL®) indicated for the prevention of Cholera and, in some countries, prevention of diarrhea caused by ETEC. The Group has proprietary vaccines in development including candidates against Pseudomonas aeruginosa, Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company's value proposition and include vaccines being developed using Valneva's innovative and validated technology platforms (EB66®vaccine production cell line, IC31®adjuvant).

Valneva is listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Scotland, Canada and Sweden with approximately 400 employees. More information is available at www.valneva.com.

Contact : Laetitia Bachelot-Fontaine Teresa Pinzolits

Head of Investor Relations Corporate Communications Specialist

& Corporate Communications T +43-1-206 20-1116

T +02-28-07-14-19 M +43-676-84 55 67 357

M +33 (0)6 4516 7099

Communications@valneva.com

Valneva SE published this content on 12 May 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 12 May 2016 08:22:08 UTC.

Public permalinkhttp://www.publicnow.com/view/67306B2FAE9A5768D2E35D52DDAFD3287EB0EA2B